Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ICMT | O60725 | 9/20 | 0.52 |
| ▸ | FNTA | P49354 | 2/20 | 0.46 |
| ▸ | FNTB | P49356 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8977916 | 1.00 | MAPT (0.57) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL2880046 | 1.00 | MAPT (0.57) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL4352903 | 1.00 | MAPT (0.57) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL14663234 | 1.00 | MAPT (0.57) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL14596316 | 1.00 | MAPT (0.57) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL8977914 | 1.00 | MAPT (0.57) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL1741964 | 0.88 | MAPT (0.53) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL3402724 | 0.88 | MAPT (0.53) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL15527709 | 0.86 | MAPT (0.51) | MAPTALDH1A1MEN1TRPA1KMT2A | |
| SCHEMBL2821557 | 0.85 | MAPT (0.65) | MAPTALDH1A1MEN1TRPA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333483-A1 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION | 2017-11-23 | — | — | US | disclosed |
| US-20170333483-A1 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION | 2017-11-23 | — | — | US | disclosed |
| US-9737567-B2 | Methods for enhancing hematopoietic stem/progenitor cell engraftment | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737567-B2 | Methods for enhancing hematopoietic stem/progenitor cell engraftment | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-08-22 | — | — | US | disclosed |
| US-20150272996-A1 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION | 2015-10-01 | — | — | US | disclosed |
| US-20150272996-A1 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION | 2015-10-01 | — | — | US | disclosed |
| US-9051548-B2 | Methods for enhancing hematopoietic stem/progenitor cell engraftment | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051548-B2 | Methods for enhancing hematopoietic stem/progenitor cell engraftment | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2015-06-09 | — | — | US | disclosed |
| US-20110053901-A1 | ACETYL MIMIC COMPOUNDS FOR THE INHIBITION OF ISOPRENYL-S-CYSTEINYL METHYLTRANSFERASE | SIGNUM BIOSCIENCES, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053901-A1 | ACETYL MIMIC COMPOUNDS FOR THE INHIBITION OF ISOPRENYL-S-CYSTEINYL METHYLTRANSFERASE | SIGNUM BIOSCIENCES, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-7745589-B1 | Antibodies and unnatural substrates of prenylation enzymes for use in detecting and isolating prenylated proteins | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-06-29 | — | — | US | disclosed |
| WO-2009102997-A2 | ACETYL MIMIC COMPOUNDS FOR THE INHIBITION OF ISOPRENYL-S-CYSTEINYL METHYLTRANSFERASE | SIGNUM BIOSCIENCES, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053901-A1 | ACETYL MIMIC COMPOUNDS FOR THE INHIBITION OF ISOPRENYL-S-CYSTEINYL METHYLTRANSFERASE | MPO, CYSLTR1, HNMT | MAPT 1682/4885ALDH1A1 2137/4885MEN1 4170/4885 |
| US-20150272996-A1 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT | HCLS1, HGF, MCL1 | MAPT 4785/4885ALDH1A1 173/4885MEN1 3334/4885 |
| US-20170333483-A1 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT | HCLS1, HGF, MCL1 | MAPT 4785/4885ALDH1A1 173/4885MEN1 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.